chemieunternehmen.com

Evotec SE announced today that the Company expands its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-clinical-and-commercial-drug-substance-manufacturing-with-acquisition-of-central-glass-germany-6207

Evotec announces that the Company has been selected as a winner of the 2022 R&D 100 Award in the following category: Software and Services for their multi-omics analysis platform EVOpanHunter. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-wins-rd-100-award-for-evopanhunter-6209

The Project to Accelerate New Treatments for Tuberculosis collaboration announced today the execution of a joint development agreement supporting the progression of two investigational tuberculosis combination treatment regimens into phase 2 clinical development. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/pan-tb-collaboration-to-advance-investigational-tuberculosis-drug-regimens-to-phase-2-clinical-trials-6205

Evotec SE today announced its financial results for the first half-year of 2022. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-reports-results-for-the-first-half-year-2022-and-provides-corporate-updates-6204